Exenatide lowered intracranial pressure in women with IIH in a placebo-controlled trial

In May 2023, a randomized, placebo-controlled trial found that exenatide, a GLP-1 drug, lowered intracranial pressure in women with active idiopathic intracranial hypertension ^[1]. The trial measured pressure with telemetric catheters, devices placed in the body that transmit pressure readings ^[1].

Idiopathic intracranial hypertension, or IIH, is a condition in which pressure inside the skull is elevated without another identified cause. The trial enrolled women whose disease was active at the time of treatment ^[1]. The report describes the design as randomized and placebo-controlled ^[1].

The report describes the result as opening a new research direction for the GLP-1 drug class ^[1]. GLP-1 drugs are a family of medicines that includes several different molecules, and exenatide is the one tested in this trial ^[1].

Exenatide is not the same molecule as semaglutide, which is sold as Ozempic, Wegovy and Rybelsus, or as tirzepatide, sold as Mounjaro and Zepbound, or as orforglipron, sold as Foundayo. Results were reported for exenatide only ^[1].

What is not yet known

Several details that would help put the finding in context have not been reported. These include how many women took part, the dose and form of exenatide used, and how long treatment lasted ^[1].

The size of the drop in intracranial pressure has not been reported, and neither has whether the difference from placebo was statistically significant ^[1]. It also has not been reported whether participants' headaches, vision or other symptoms changed, or what side effects occurred ^[1].

Why it matters for patients

People taking semaglutide or tirzepatide should not read this trial as evidence about their own medicine. The drug studied was exenatide, and the findings do not show what semaglutide, tirzepatide or orforglipron do in IIH ^[1].

For people living with IIH, the result is a research signal rather than a treatment option. The report does not establish a dose of exenatide that would be safe or effective for the condition, and it does not show whether the pressure change translated into feeling better ^[1]. Nothing in the report indicates that a GLP-1 drug is approved to treat IIH ^[1].

Treatment decisions for IIH stay with clinicians. The trial does not offer guidance on using exenatide for the condition outside of research ^[1].

What happens next

No follow-up study, larger trial, regulatory action or timeline has been reported ^[1]. Replication in a larger trial would be needed before a result like this could inform care, and no such trial has been disclosed ^[1].

IIH has drawn attention from GLP-1 researchers because the drug class affects metabolism and fluid regulation in ways that scientists are still working out, but that work is early ^[1].